Page last updated: 2024-11-05

cycloguanil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cycloguanil is a synthetic antimalarial drug that is a prodrug of cycloguanil, which is a potent inhibitor of dihydrofolate reductase (DHFR). DHFR is an enzyme essential for the biosynthesis of tetrahydrofolic acid, a critical coenzyme involved in DNA synthesis. Cycloguanil is used in combination with other antimalarials, particularly mefloquine, to prevent malaria. It is widely used in areas where resistance to chloroquine is high. The drug is orally administered and is typically well-tolerated. Cycloguanil is studied extensively because of its potential to treat and prevent malaria, a significant public health problem in many parts of the world. Research is ongoing to develop new drugs and drug combinations that are more effective and have fewer side effects. Cycloguanil is considered a valuable tool in the fight against malaria.'

cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9049
CHEMBL ID747
CHEBI ID135029
SCHEMBL ID140230
MeSH IDM0085872

Synonyms (47)

Synonym
LS-13958
1-(4-chlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
CGT ,
malarone
cycloguanil
wr 5473
516-21-2
1-(4-chlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine
1-(4-chlorophenyl)-1,6-dihydro-6,6-dimethyl-1,3, 5-triazine-2,4-diamine
1-p-chlorophenyl-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine
cycloguanilum
1,3,5-triazine-2,4-diamine, 1,6-dihydro-1-(4-chlorophenyl)-6,6-dimethyl-
brn 0229760
1-(p-chlorophenyl)-4,6-diamino-2,2-dimethyl-1,2-dihydro-s-triazine
bn2410
bn-24-10
4-amino-6-p-chloroanilino-1,2-dwuhydro-2,2-dwumethylo-1,3,5-trojazyna [polish]
cycloguanyl
s-triazine, 1,2-dihydro-1-(p-chlorophenyl)-4,6-diamino-2,2-dimethyl-
chlorguanide triazine
MAYBRIDGE1_004316
chembl747 ,
bdbm18792
CHEBI:135029
1cy ,
AKOS001637073
4-amino-6-p-chloroanilino-1,2-dwuhydro-2,2-dwumethylo-1,3,5-trojazyna
unii-26rm326wvn
26rm326wvn ,
4-26-00-01176 (beilstein handbook reference)
4,6-diamino-1-(p-chlorophenyl)-1,2-dihydro-2,2-dimethyl-s-triazine
cycloguanil [who-dd]
1-(4-chlorophenyl)-1,6-dihydro-6,6-dimethyl-1,3,5-triazine-2,4-diamine
cycloguanil [mi]
SCHEMBL140230
1,3,5-triazine-2,4-diamine, 1-(4-chlorophenyl)-1,6-dihydro-6,6-dimethyl-
DTXSID9022867
CCG-250330
gtpl10027
Q5198706
VIL ,
DB14763
BRD-K75179562-003-01-1
SB73658
CS-0012453
HY-12784
EN300-818812

Research Excerpts

Overview

Cycloguanil is a known dihydrofolate-reductase (DHFR) inhibitor, but there is no evidence of its activity on pteridine reductase (PTR) PTR is the main metabolic bypass to DHFR inhibition in trypanosomatid parasites.

ExcerptReferenceRelevance
"Cycloguanil is a known dihydrofolate-reductase (DHFR) inhibitor, but there is no evidence of its activity on pteridine reductase (PTR), the main metabolic bypass to DHFR inhibition in trypanosomatid parasites. "( Structural Insights into the Development of Cycloguanil Derivatives as
Bertolacini, CP; Borsari, C; Cordeiro-da-Silva, A; Costi, MP; Gul, S; Kuzikov, M; Landi, G; Linciano, P; Mangani, S; Moraes, CB; Pozzi, C; Witt, G, 2019
)
2.22

Pharmacokinetics

There were no significant differences in any of the pharmacokinetic parameters of atovaquone, proguanil or cycloguanil between patients from Thailand and Zambia. Plasmodium falciparum malaria has no effect on the pharmacokinetic  parameters for chlorproguanil, dapsone or chlorcycloguanIL.

ExcerptReferenceRelevance
"A pharmacokinetic study with 12-hourly doses of 100 mg proguanil hydrochloride over 15 days has been conducted in six adult male Malaysian volunteers."( Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride.
Jamaludin, A; Mohamad, M; Navaratnam, V; Wernsdorfer, WH; Yeoh, PY, 1990
)
0.53
" Pharmacokinetic analysis showed that this observation resulted from a reduced oral clearance of proguanil in these individuals (245, 534 and 552 ml min-1) compared with the rest of the population (858 +/- 482 ml min-1)."( The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.
Breckenridge, AM; Edwards, G; Helsby, NA; Howells, RE; Ward, SA, 1990
)
0.28
" The drug was rapidly absorbed reaching a peak concentration in the blood within 3 h, and declining slowly thereafter to give a terminal phase elimination half life of 11."( The pharmacokinetics of proguanil in human subjects following a single oral dose.
Chiluba, EM; Fletcher, KA; Price, AH, 1987
)
0.27
"The pharmacokinetic parameters of chlorproguanil (Lapudrine) and its active metabolite, chlorcycloguanil, were determined in 6 healthy male volunteers after a single oral dose of 4 Lapudrine tables (80 mg)."( Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine.
Edstein, MD; Rieckmann, KH; Veenendaal, JR, 1988
)
0.49
" The pharmacokinetic properties of proguanil were similar during and after pregnancy."( Single dose pharmacokinetics of proguanil and its metabolites in pregnancy.
Moody, RR; Nosten, F; Taylor, RB; ter Kuile, F; Wangboonskul, J; White, NJ, 1993
)
0.29
" The geometric mean elimination half-life (t1/2) of atovaquone was 57."( Lack of a pharmacokinetic interaction between atovaquone and proguanil.
Gillotin, C; Mamet, JP; Veronese, L, 1999
)
0.3
"To determine the pharmacokinetic profiles of atovaquone (ATO), proguanil (PROG) and its active metabolite cycloguanil (CYCLO) with respect to possible accumulation and kinetic interaction upon repeated dosing with Malarone."( Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.
Ashton, M; Bergqvist, Y; Björkman, A; Johansson, I; Lindegårdh, N; Nivelius, S; Thapar, MM, 2002
)
0.53
" Single-dose and steady-state pharmacokinetic parameters were determined for each individual."( Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.
Ashton, M; Bergqvist, Y; Björkman, A; Johansson, I; Lindegårdh, N; Nivelius, S; Thapar, MM, 2002
)
0.31
" The pharmacodynamic interactions among atovaquone, proguanil and its metabolite cycloguanil were investigated in 4 Plasmodium falciparum parasite strains by culture assays in vitro."( Pharmacodynamic interactions among atovaquone, proguanil and cycloguanil against Plasmodium falciparum in vitro.
Björkman, A; Gupta, S; Spindler, C; Thapar, MM; Wernsdorfer, WH,
)
0.6
" Blood samples were taken for pharmacokinetic investigations of atovaquone, proguanil, and cycloguanil up to 288 h (day 14) after the last dose."( The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.
Kioy, D; Konsil, J; Manyando, C; Miller, GB; Mulenga, M; Na-Bangchang, K; Ruengweerayut, R, 2005
)
0.55
" There were no significant differences in any of the pharmacokinetic parameters of atovaquone, proguanil or cycloguanil between patients from Thailand and Zambia."( The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.
Kioy, D; Konsil, J; Manyando, C; Miller, GB; Mulenga, M; Na-Bangchang, K; Ruengweerayut, R, 2005
)
0.54
"The pharmacokinetics of atovaquone and cycloguanil appeared to be influenced by the pregnancy status, resulting in an decrease in the Cmax and AUC of approximately twofold."( The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.
Kioy, D; Konsil, J; Manyando, C; Miller, GB; Mulenga, M; Na-Bangchang, K; Ruengweerayut, R, 2005
)
0.6
"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00."( Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.
Aarons, L; Bojang, K; Edwards, G; Hughes, D; Manyando, C; Simpson, JA; Ward, S; Watkins, WA; Winstanley, P, 2006
)
0.33
"Plasmodium falciparum malaria has no effect on the pharmacokinetic parameters for chlorproguanil, dapsone or chlorcycloguanil."( Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.
Aarons, L; Bojang, K; Edwards, G; Hughes, D; Manyando, C; Simpson, JA; Ward, S; Watkins, WA; Winstanley, P, 2006
)
0.54

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37

Dosage Studied

The profiles and peak/trough ratios of proguanil and cycloguanil with 12-hourly dosing offer better prospects for protection against malaria. Blood was sampled before dosing and at regular intervals over 8 days when proguanIL was given, and over 17 days when atovaquone was given.

ExcerptRelevanceReference
" carinii in vitro, a clinical trial of reduced dosage of dapsone given prophylactically to human beings is suggested."( Dapsone in low doses prevents Pneumocystis carinii pneumonia in the rat model.
González-Ruiz, A; Haworth, SJ; O'Neil, AB; Warhurst, DC, 1991
)
0.28
" The profiles and peak/trough ratios of proguanil and cycloguanil with 12-hourly dosing offer better prospects for protection against malaria than those obtained with 24-hourly doses of 200 mg proguanil hydrochloride, the current routine in malaria chemoprophylaxis."( Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride.
Jamaludin, A; Mohamad, M; Navaratnam, V; Wernsdorfer, WH; Yeoh, PY, 1990
)
0.78
" The currently recommended dosage regimen appears to be appropriate for extensive metabolisers of proguanil."( The multiple dose pharmacokinetics of proguanil.
Breckenridge, AM; Edwards, G; Helsby, NA; Ward, SA, 1993
)
0.29
" For the assay of proguanil, cycloguanil and atovaquone, blood was sampled before dosing and at regular intervals over 8 days when proguanil was given, and over 17 days when atovaquone was given."( Lack of a pharmacokinetic interaction between atovaquone and proguanil.
Gillotin, C; Mamet, JP; Veronese, L, 1999
)
0.59
"To determine the pharmacokinetic profiles of atovaquone (ATO), proguanil (PROG) and its active metabolite cycloguanil (CYCLO) with respect to possible accumulation and kinetic interaction upon repeated dosing with Malarone."( Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.
Ashton, M; Bergqvist, Y; Björkman, A; Johansson, I; Lindegårdh, N; Nivelius, S; Thapar, MM, 2002
)
0.53
" Subsequently blood and urine samples were collected after drug dosing as before."( Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
Adithan, C; Rajan, S; Shashindran, C; Tushar, T; Vinod, T, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
EC 1.5.1.3 (dihydrofolate reductase) inhibitorAn EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of dihydrofolate reductase (EC 1.5.1.3).
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
antiparasitic agentA substance used to treat or prevent parasitic infections.
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
antiprotozoal drugAny antimicrobial drug which is used to treat or prevent protozoal infections.
antifolateAn antimetabolite that impairs the action of folic acids
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triazinesCompounds based on a triazine skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)5.80000.00001.77679.2000AID158542
Dihydrofolate reductaseHomo sapiens (human)Ki14.48850.00000.37564.9000AID1485221; AID1485256; AID518563
Dihydrofolate reductaseGallus gallus (chicken)Ki0.11220.11220.21580.3311AID56484
Dihydrofolate reductaseLacticaseibacillus caseiKi17.37800.00001.26756.3096AID57924
Dihydrofolate reductaseEscherichia coli K-12IC50 (µMol)20.91000.00150.55126.8000AID1255685
Dihydrofolate reductaseEscherichia coli K-12Ki1.02000.00000.37904.0200AID1255686
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium falciparum K1IC50 (µMol)24.97330.00151.11635.8000AID158537; AID158539; AID158540; AID158541; AID158542; AID158543
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium falciparum K1Ki0.43620.00000.43696.6645AID141257; AID1797769; AID211986; AID211988; AID219249; AID219250; AID238767; AID58127; AID58128; AID58250; AID58251; AID58252; AID58282; AID58283; AID58284; AID58285; AID58286
Dihydrofolate reductasePneumocystis cariniiIC50 (µMol)0.45000.00060.54766.2000AID55836
Dihydrofolate reductasePneumocystis cariniiKi36.37770.00000.04680.1520AID1485253; AID55851; AID55853
Dihydrofolate reductaseRattus norvegicus (Norway rat)IC50 (µMol)0.11000.00060.35076.2000AID57974
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseEscherichia coli K-12Kd11.77000.00001.24596.6000AID1255683
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (40)

Processvia Protein(s)Taxonomy
heart valve developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
ventricular septum developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
aorta developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of inflammatory responsecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
establishment of endothelial barriercGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to mechanical stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cAMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cGMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxinecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of gene expressioncGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of mitochondrion organizationcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseGallus gallus (chicken)
response to methotrexateDihydrofolate reductaseGallus gallus (chicken)
tetrahydrofolate metabolic processDihydrofolate reductaseGallus gallus (chicken)
tetrahydrofolate biosynthetic processDihydrofolate reductaseGallus gallus (chicken)
dihydrofolate metabolic processDihydrofolate reductaseGallus gallus (chicken)
folic acid metabolic processDihydrofolate reductaseGallus gallus (chicken)
10-formyltetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to xenobiotic stimulusDihydrofolate reductaseEscherichia coli K-12
folic acid biosynthetic processDihydrofolate reductaseEscherichia coli K-12
one-carbon metabolic processDihydrofolate reductaseEscherichia coli K-12
response to methotrexateDihydrofolate reductaseEscherichia coli K-12
tetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to antibioticDihydrofolate reductaseEscherichia coli K-12
dihydrofolate metabolic processDihydrofolate reductaseEscherichia coli K-12
folic acid metabolic processDihydrofolate reductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
magnesium ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
zinc ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
TPR domain bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
phosphate ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein homodimerization activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseGallus gallus (chicken)
dihydrofolate reductase activityDihydrofolate reductaseGallus gallus (chicken)
NADP bindingDihydrofolate reductaseGallus gallus (chicken)
dihydrofolate reductase activityDihydrofolate reductaseEscherichia coli K-12
protein bindingDihydrofolate reductaseEscherichia coli K-12
folic acid bindingDihydrofolate reductaseEscherichia coli K-12
oxidoreductase activityDihydrofolate reductaseEscherichia coli K-12
NADP bindingDihydrofolate reductaseEscherichia coli K-12
methotrexate bindingDihydrofolate reductaseEscherichia coli K-12
dihydrofolic acid bindingDihydrofolate reductaseEscherichia coli K-12
NADP+ bindingDihydrofolate reductaseEscherichia coli K-12
NADPH bindingDihydrofolate reductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
endoplasmic reticulumcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
Golgi apparatuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
presynaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
synaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial matrixcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseGallus gallus (chicken)
cytosolDihydrofolate reductaseEscherichia coli K-12
cytosolDihydrofolate reductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (179)

Assay IDTitleYearJournalArticle
AID1797769Antimalarial Testing In Vitro (IC50) and Measurement of Inhibition Constant (Ki) from Article 10.1038/nsb921: \\Insights into antifolate resistance from malarial DHFR-TS structures.\\2003Nature structural biology, May, Volume: 10, Issue:5
Insights into antifolate resistance from malarial DHFR-TS structures.
AID1485234Selectivity ratio of EC50 for Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells to EC50 for Influenza B virus B/Ned/537/05 infected in MDCK cells2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID529905Antiplasmodial activity against Plasmodium falciparum harboring K1 allele group of msp1, 3D7 allele group of msp2 gene and 94 bp of 7A11, 196bp of C4M79 and 336bp of C4M69 locus measured on day 23 by [3H]hypoxanthine incorporation assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
AID1485241Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID211986Binding affinity was evaluated as inhibition of mutant (C59R + S108N) Plasmodium falciparum DHFR-TS.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.
AID576706Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L and S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1485251Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID231314Ratio of binding affinity for mutant (N51I+C59R+S108N+I164L) to that of wild type dihydrofolate reductase2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID231312Ratio of binding affinity for mutant (C59R+S108N+I164L) to that of wild type dihydrofolate reductase2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID233567The ratio of SD90 of the quinine htdrocloride, to the SD90 of the test substance for the Dose of mg/kg1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID65359Inhibition of growth of methotrexate-resistant (MB1428) strain of Escherichia coli cells.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.
AID95845In vitro cytotoxicity against Plasmodium falciparum infected KB cell line2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID158849Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Structure-activity relationships of novel anti-malarial agents. Part 2: cinnamic acid derivatives.
AID158852Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes by semiautomated micro dilution2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID158852Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes by semiautomated micro dilution2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID158864Antimalarial activity against Plasmodium falciparum 3D7 in erythrocytes2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
AID58128Binding affinity towards mutant dihydrofolate reductase (C59R+S108N+I164L DHFR) of Plasmodium falciparum2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID238767Inhibition constant against Plasmodium falciparum dihydrofolate reductase2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
AID1737544Antimalarial activity against Plasmodium falciparum CsI-2 harboring DHFR C59R/S108N/I164L mutant infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 20 hrs followed by [3H]-hypoxanthine addition measured 2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID1485233Cytotoxicity against human Calu3 cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID235841Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum TM4/8.2 infected BC cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID158543In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase wild type (TM4/8.2)2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID245428In vitro minimum inhibiting concentration for schizont maturation from ring stage parasite over 40 hrs2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Syntheses of 2,4,6-trisubstituted triazines as antimalarial agents.
AID58127Binding affinity towards mutant dihydrofolate reductase (A16V+S108T DHFR) of Plasmodium falciparum.2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1255686Inhibition of Escherichia coli DHFR assessed as NADP formation by quadratic Morrison plot analysis2015European journal of medicinal chemistry, Oct-20, Volume: 103Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase.
AID518565Selectivity ratio of Ki for recombinant Plasmodium falciparum V1/S DHFR S108N, N51I, C59R, I164L mutant to Ki for wild type Plasmodium falciparum DHFR2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID118268No of toxic deaths at dose of 640 mg/kg1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID57924Inhibitory activity against Lactobacillus casei dihydrofolate reductase (DHFR)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Crystallography, quantitative structure-activity relationships, and molecular graphics in a comparative analysis of the inhibition of dihydrofolate reductase from chicken liver and Lactobacillus casei by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(substituted
AID57583Inhibition of dihydrofolate reductase (DHFR) from Escherichia coli.1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID55836Inhibitory activity against dihydrofolate reductase in Pneumocystis carinii at 37 centigrade.1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID518562Binding affinity to recombinant Plasmodium falciparum V1/S DHFR S108N, N51I, C59R, I164L mutant by competitive binding assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID231311Ratio of binding affinity for mutant (A16V+S108T) to that of wild type dihydrofolate reductase2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID235842Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum TM4/8.2 infected KB cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID216031In vitro cytotoxicity against Plasmodium falciparum infected vero cell line.2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID158539In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase C59R/S108N (K1CB1) mutant2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID56484Inhibitory activity against isolated chicken liver dihydrofolate reductase (DHFR)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Crystallography, quantitative structure-activity relationships, and molecular graphics in a comparative analysis of the inhibition of dihydrofolate reductase from chicken liver and Lactobacillus casei by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(substituted
AID56937Inhibitory activity against human lymphoblastoid cell (WIL2) dihydrofolate reductase (DHFR)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Inhibition of human dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(substituted-phenyl)-s-triazine s. A quantitative structure-activity relationship analysis.
AID518561Binding affinity to wild type Plasmodium falciparum DHFR by competitive binding assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1426081Agonist activity at mouse TAAR5 expressed in HEK293 cells assessed as cAMP accumulation after 20 mins by BRET assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID158540In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase C59R+S108N/I164L (Csl-2) mutant2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID235839Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum Csl-2 infected KB cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID116236Antimalarial effect against trophozoite induced Plasmodium berghei in mice (Mus musculus) at dosage of 160 mg/kg after subcutaneous administration; No data1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1485235Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1737542Antimalarial activity against Plasmodium falciparum K1CB1 harboring DHFR C59R/S108T mutant infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 20 hrs followed by [3H]-hypoxanthine addition measured after 2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID1485232Selectivity ratio of EC50 for Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells to EC50 for Influenza B virus B/Ned/537/05 infected in MDCK cells2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1625412Antiplasmodial activity against chloroquine/antifolate-sensitive Plasmodium falciparum TM4 infected in human RBC incubated for 18 to 20 hrs by microdilution radioisotope method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Antimalarial Oxoprotoberberine Alkaloids from the Leaves of Miliusa cuneata.
AID158537In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase A16V/S108T (T9/94RC17) mutant2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID116255Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at dosage of 640 mg/kg after subcutaneous administration; No data1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1485246Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID116238Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after 20 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1145686Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID236906Partition coefficient (logP)2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Syntheses of 2,4,6-trisubstituted triazines as antimalarial agents.
AID1485247Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID235847Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum TM4/8.2 infected Vero cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1255683Binding affinity to Escherichia coli DHFR at 500 uM using spyro orange reporter dye by differential scanning fluorimetry2015European journal of medicinal chemistry, Oct-20, Volume: 103Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase.
AID1485248Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID529907Antiplasmodial activity against Plasmodium falciparum harboring K1 allele group of msp1, 3D7 allele group of msp2 gene and 94 bp of 7A11, 196bp of C4M79 and 336bp of C4M69 locus measured on day 23 by [3H]hypoxanthine incorporation assay relative to contro2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
AID235840Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum Csl-2 infected Vero cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID157697Anti-malarial activity against Plasmodium falciparum Dd22003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID157697Anti-malarial activity against Plasmodium falciparum Dd22003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID1145673Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 to IC50 for sensitive Streptococcus faecium ATCC 80431977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID219249Binding affinity towards wild-type dihydrofolate reductase of Plasmodium falciparum.2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1426079Agonist activity at human TAAR1 expressed in HEK293 cells assessed as cAMP accumulation at 10 uM after 20 mins by BRET assay relative to beta-PEA2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID152294Growth inhibition (IC50) against Plasmodium falciparum wild-type TM4/8.22000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
AID1485231Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID116376Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 80 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID576702Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R and S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID58251Binding affinity towards mutant dihydrofolate reductase (N51I+C59R+S108N+I164L DHFR) of Plasmodium falciparum2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID576704Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L, S58R, T61M, S117T mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID58286Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with triple (C59R + S108N + I164L) mutations2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID1485256Inhibition of human DHFR2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID576699Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID576703Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R, T61M and S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1505094Antiplasmodial activity against drug-sensitive blood stage Plasmodium falciparum 3D7 by SYBR green 1 staining based fluorescence assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Isolation, Derivative Synthesis, and Structure-Activity Relationships of Antiparasitic Bromopyrrole Alkaloids from the Marine Sponge Tedania brasiliensis.
AID1737543Antimalarial activity against Plasmodium falciparum W2 harboring DHFR N51I/C59R/S108N mutant infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 20 hrs followed by [3H]-hypoxanthine addition measured afte2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID248852In vitro antimalarial activity for DHFR wild-type, chloroquine and pyrimethamine-resistant Plasmodium falciparum W22005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines.
AID232440Ratio of inhibitions against mutant and wild type (WT) Plasmodium falciparum DHFR-TS.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.
AID116247Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 320 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID576705Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1737533Inhibition of Plasmodium falciparum DHFR expressed in Escherichia coli BL21 using DHF as substrate by spectrophotometric analysis2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID1201532Inhibition of Plasmodium falciparum DHFR after 48 hrs2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID1426077Agonist activity at mouse TAAR1 expressed in HEK293 cells assessed as cAMP accumulation at 10 uM after 20 mins by BRET assay relative to beta-PEA2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1485253Inhibition of Pneumocystis carinii DHFR2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID158038Inhibitory concentration against multidrug-resistant Plasmodium falciparum Dd2.2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Structure-activity relationships of novel anti-malarial agents. Part 4: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides.
AID158541In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase CN51I/C59R/S108N/I164L (V1/S) mutant2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID55851Binding affinity was reported with purified recombinant Pneumocystis carinii Dihydrofolate reductase1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID1145678Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1145689Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as dose required to survivors for period of 60 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID159001In vitro antimalarial activity against Plasmodium falciparum K12001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
AID1485244Cytotoxicity against dog MDCK cells assessed as alterations in normal cell morphology measured after 5 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID255515Minimum inhibitory concentration against Plasmodium falciparum NF-54 after 40 hrs2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
Synthesis of 2-[3,5-substituted pyrazol-1-yl]-4,6-trisubstituted triazine derivatives as antimalarial agents.
AID1485243Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1145675Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1145674Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1255681Binding affinity to Escherichia coli DHFR assessed as change in melting temperature at 500 uM using spyro orange reporter dye by differential scanning fluorimetry2015European journal of medicinal chemistry, Oct-20, Volume: 103Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase.
AID1737545Antimalarial activity against Plasmodium falciparum V1/S harboring DHFR N51I/C59R/S108N/I164L mutant infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 20 hrs followed by [3H]-hypoxanthine addition measu2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID1737540Antimalarial activity against Plasmodium falciparum TM4/8.2 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 20 hrs followed by [3H]-hypoxanthine addition measured after 20 hrs by radioactivity method2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID576701Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L and S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID235845Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum V1/S infected KB cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1737535Inhibition of Plasmodium falciparum DHFR C59R/S108T mutant expressed in Escherichia coli BL21 using DHF as substrate by spectrophotometric analysis2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID576707Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R and S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID158865Antimalarial activity against Plasmodium falciparum Dd2 in erythrocytes2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
AID141257Inhibition constant (Ki mut) against A16V+S108T Mutant DHFRs of Plasmodium falciparum2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
AID41220In vitro cytotoxicity against Plasmodium falciparum infected BC cell line.2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID233569The ratio of SD90 of the quinine htdrocloride, to the SD90 of the test substance for the Dose of mg/kg; No data1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1145677Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID235838Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum Csl-2 infected BC cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID211988Binding affinity was evaluated as inhibition of recombinant wild type (WT) Plasmodium falciparum DHFR-TS.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.
AID748933Antiplasmodial activity against chloroquine and antifolate-sensitive Plasmodium falciparum TM4 after 24 hrs by [3H]-hypoxanthine incorporation assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID58250Binding affinity towards mutant dihydrofolate reductase (N51I+C59R+S108N DHFR) of Plasmodium falciparum2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1145671Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID576710Ratio of IC50 for Plasmodium falciparum TM91c235 harboring DHFR F57L, S58R, T61M, S117T mutant to IC50 for Plasmodium falciparum D62010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID518563Binding affinity to human recombinant DHFR expressed in Escherichia coli BL21(DE3) by competitive binding assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1255685Inhibition of Escherichia coli DHFR assessed as NADP formation2015European journal of medicinal chemistry, Oct-20, Volume: 103Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase.
AID518564Selectivity ratio of Ki for human recombinant DHFR to Ki for wild type Plasmodium falciparum DHFR2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1145676Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 to IC50 for sensitive Lactobacillus casei ATCC 74691977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID58284Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with single A16V mutation2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID1485239Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1737536Inhibition of Plasmodium falciparum DHFR N51I/C59R/S108N mutant expressed in Escherichia coli BL21 using DHF as substrate by spectrophotometric analysis2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID1625413Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 infected in human RBC incubated for 18 to 20 hrs by microdilution radioisotope method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Antimalarial Oxoprotoberberine Alkaloids from the Leaves of Miliusa cuneata.
AID58252Inhibition constant against wild-type PfDHFR (Plasmodium falciparum dihydrofolate reductase)2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID1485249Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485250Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID65357Inhibition of growth of methotrexate-sensitive (MB1417) strain of Escherichia coli cells.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.
AID1737537Inhibition of Plasmodium falciparum DHFR C59R/S108N/I164L mutant expressed in Escherichia coli BL21 using DHF as substrate by spectrophotometric analysis2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID1737541Antimalarial activity against Plasmodium falciparum T9/94 RC17 harboring DHFR A16V/S108T mutant infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 20 hrs followed by [3H]-hypoxanthine addition measured a2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID158542In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase N51I/C59R/S108N (W2)2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1485221Inhibition of human DHFR using dihydrofolate as substrate after 180 secs by spectrophotometric analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID57470Inhibitory activity against dihydrofolate reductase (DHFR) isolated from murine L5178Y tumor cells resistant and sensitive to methotrexate1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID116250Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after 40 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID116246Antimalarial effect against trophozoite induced Plasmodium berghei in mice (Mus musculus) at dosage of 320 mg/kg after subcutaneous administration; No data1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID119314Number of toxic deaths at a dose of 640 mg/kg1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID576697Antimalarial activity against Plasmodium falciparum D6 infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1145683Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1485238Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID231313Ratio of binding affinity for mutant (N51I+C59R+S108N) to that of wild type dihydrofolate reductase2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID576709Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L, S58R, T61M, S117T mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1485240Cytotoxicity against human HeLa cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID152148Inhibition of Plasmodium falciparum T9/94 mutant2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
AID116237Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at dosage of 160 mg/kg after subcutaneous administration; no data1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1145688Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as active dose required to increase of 100% in mean survival time1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID57974Inhibitory activity against dihydrofolate reductase in rat liver.1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID219250Evaluated for inhibition constant (Ki wt) against Wild-type dihydrofolate reductase of Plasmodium falciparum2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
AID141258Evaluated for activity of compound relative to Cycloguanil2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
AID1485236Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485245Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID599179Antimalarial activity against chloroquine and cycloguanil-resistant Plasmodium falciparum FCR-3/Gambia ring stage infected in human red blood cells assessed as inhibition of [3H]-hypoxanthine incorporation incubated 24 hrs before addition of [3H]-hypoxant2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Expeditious synthesis and biological evaluation of novel 2,N6-disubstituted 1,2-dihydro-1,3,5-triazine-4,6-diamines as potential antimalarials.
AID55853Inhibition of dihydrofolate reductase (DHFR) from Pneumocystis carinii.1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Quantitative structure-activity relationships of the inhibition of Pneumocystis carinii dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(X-phenyl)-s-triazines.
AID219253Evaluated for activity of relative to Cycloguanil2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
AID158017In vitro antimalarial activity against Plasmodium falciparum W22001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
AID1145682Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1737538Inhibition of Plasmodium falciparum DHFR N51I/C59R/S108N/I164L mutant expressed in Escherichia coli BL21 using DHF as substrate by spectrophotometric analysis2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID576708Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R, T61M and S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID236571In vitro PKa value was determined2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Syntheses of 2,4,6-trisubstituted triazines as antimalarial agents.
AID58283Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with quadruple (N51I + C59R + S108N + I164L) mutations2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID1485237Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485255Cytotoxicity against African green monkey Vero cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID576698Antimalarial activity against Plasmodium falciparum TM91c235 harboring DHFR F57L, S58R, T61M, S117T mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID248853In vitro antimalarial activity for DHFR wild-type, chloroquine and pyrimethamine-sensitive Plasmodium falciparum D62005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines.
AID116259Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at dosage of 640 mg/kg after subcutaneous administration; No data1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1485242Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID576700Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1145684Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1145679Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 to IC50 for sensitive Pediococcus cerevisiae ATCC 8081977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1737534Inhibition of Plasmodium falciparum DHFR A16V/S108T mutant expressed in Escherichia coli BL21 using DHF as substrate by spectrophotometric analysis2020European journal of medicinal chemistry, Jun-01, Volume: 195Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
AID58282Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with double (A16V + S108T) mutations2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID1145680Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID158715Inhibition against Plasmodium falciparum Dd2 in erythrocytes in semiautomated micro dilution assay2003Bioorganic & medicinal chemistry letters, Jul-07, Volume: 13, Issue:13
Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.
AID1145685Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1505096Antiplasmodial activity against chloroquine/cycloguanil/pyrimethamine-resistant blood stage Plasmodium falciparum K1 by SYBR green 1 staining based fluorescence assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Isolation, Derivative Synthesis, and Structure-Activity Relationships of Antiparasitic Bromopyrrole Alkaloids from the Marine Sponge Tedania brasiliensis.
AID1145681Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID58285Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with single S108T mutation2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID1145672Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID227230Selectivity ratio of growth inhibition against Plasmodium falciparum TM4/8.2(wild-type) and T9/94(mutant)2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
AID229361Ratio of inhibitory constant of mutant by wild-type DHFRs of Plasmodium falciparum2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (219)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (19.18)18.7374
1990's67 (30.59)18.2507
2000's68 (31.05)29.6817
2010's38 (17.35)24.3611
2020's4 (1.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.55 (24.57)
Research Supply Index5.51 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index50.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (6.93%)5.53%
Reviews3 (1.30%)6.00%
Case Studies1 (0.43%)4.05%
Observational0 (0.00%)0.25%
Other211 (91.34%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]